drug_type
RELEVANT_DRUG
intervention_type
Biologic (TCR-based bispecific T-cell engager)
drug_description
A bispecific, TCR-based biologic (TCER) that uses a high-affinity soluble TCR to bind a PRAME-derived peptide presented by HLA class I on tumor cells and an anti-CD3 moiety to engage and activate T cells, redirecting cytotoxicity against PRAME-positive solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antineoplastic Agents, Immunological
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
IMA402 is a TCR-based bispecific T-cell engager (TCER) that uses a high-affinity soluble TCR to bind a PRAME-derived peptide presented by HLA class I on tumor cells and an anti-CD3 moiety to recruit and activate T cells, forming an immune synapse and redirecting perforin/granzyme-mediated cytotoxicity against PRAME-positive tumors.
drug_name
IMA402
nct_id_drug_ref
NCT05958121